Background
Ipamorelin was developed in the 1990s during a broader search for growth hormone secretagogues with improved selectivity over first-generation GHRPs. Early GHRPs (e.g., GHRP-6) stimulated GH effectively but also raised cortisol and prolactin, limiting their clinical appeal. Ipamorelin's pentapeptide structure was optimized to favor GH selectivity. Despite promising pharmacology, ipamorelin has remained primarily an investigational tool rather than an approved therapy. It has been used in small clinical trials to study GH physiology and explore applications in GH deficiency and aging, but has not advanced to broad regulatory approval. Most current use outside formal research is off-label and largely unregulated.
Evidence snapshot
Ipamorelin is a synthetic pentapeptide that agonizes the ghrelin receptor (GHS-R1a) on pituitary somatotrophs, reliably producing acute GH pulses in human studies. Several short-term trials report downstream IGF-1 increases with repeated dosing, though effect size and clinical relevance vary across studies.
Compared with earlier GHRPs such as GHRP-6, ipamorelin shows greater selectivity for GH release, with minimal stimulation of cortisol and prolactin in short-term studies. This selectivity profile is one reason it has been preferred in research settings, but it does not eliminate metabolic or endocrine concerns with sustained use.
Animal models demonstrate anabolic and metabolic effects consistent with GH/IGF-1 elevation. Translation to clinically meaningful benefits in healthy or aging humans has not been established in high-quality randomized trials evaluating body composition, physical function, or long-term health outcomes.
Safety data beyond weeks to a few months are sparse. Sustained GH/IGF-1 elevation carries theoretical risks including impaired insulin sensitivity and potential promotion of pre-existing neoplasms. Ipamorelin is not approved by major regulatory agencies for anti-aging or performance enhancement; supervised use is limited to research settings.
Bioavailability & administration
Oral bioavailability is negligible — like all peptides, ipamorelin is degraded in the gastrointestinal tract before systemic absorption. Subcutaneous injection is the standard research route. After SC administration, GH levels rise within minutes and typically peak within 30–60 minutes. The peptide itself has a short plasma half-life (estimated under 2 hours), but the downstream GH/IGF-1 response persists longer. Sterile injection technique and site rotation are necessary to reduce local reactions and infection risk.
Populations studied
Human data come primarily from healthy adults and older volunteers, with some small cohorts involving GH deficiency or other endocrine conditions. Most trials are acute (single dose) or short-term (up to several weeks). Data in children, pregnant or breastfeeding individuals, and patients with active malignancy are absent or extremely limited. Use in these populations is not appropriate outside specialist-supervised research contexts.
Long-term safety & regulatory status
Long-term safety data for ipamorelin are sparse. Sustained elevation of GH and IGF-1 is associated with insulin resistance, fluid retention, joint pain, and — in those with pre-existing neoplasms — theoretical tumor promotion, based on extrapolation from acromegaly literature and exogenous GH data. Ipamorelin is not approved by the FDA, EMA, or other major regulatory agencies for anti-aging, performance enhancement, or metabolic disease. Unregulated commercial peptide products carry additional risks of microbial contamination and inaccurate dosing.
Pharmacodynamics & combination strategies
Ipamorelin acts at the level of the pituitary GHS-R1a receptor. Co-administration with GHRH analogs such as CJC-1295 is used in research protocols to amplify GH pulses through complementary mechanisms — ipamorelin increases pulse amplitude via the ghrelin receptor while GHRH analogs prolong stimulation of somatotrophs. This combination can produce larger and more sustained GH elevations than either agent alone, but also compounds uncertainty around safety, interactions, and long-term consequences. Combination use requires experienced clinical oversight.
Compound variations
Ipamorelin acetate
The acetate salt form used in research and peptide formulations. Pharmacology is equivalent to the parent peptide when doses are calculated by peptide content.
Common use case
Standard research dosing via subcutaneous injection.
Dosage note
Typical research doses: 100–500 µg SC per administration. Prepare and store according to manufacturer specifications; use strict sterile technique.
Ipamorelin + CJC-1295 (combination)
A combination pairing a GHS-R1a agonist (ipamorelin) with a GHRH analog (CJC-1295) to amplify GH pulse amplitude and duration. Used experimentally; not approved for any clinical indication.
Common use case
Research protocols targeting larger or more sustained GH increases.
Dosage note
Regimens vary by protocol. CJC-1295 has its own dosing, half-life, and safety profile distinct from ipamorelin; combination use requires clinician oversight.
Ipamorelin injection solution
Reconstituted peptide solution for subcutaneous injection. Stability and concentration depend on source, reconstitution method, and storage conditions.
Common use case
Direct subcutaneous administration in supervised research or clinical settings.
Dosage note
Follow research protocol or manufacturer guidance for reconstitution, refrigerated storage, and use-by timelines. Avoid products from unverified suppliers.
Dosage and best practices
Dosage principles
- Acute single-dose studies in humans commonly use 200–300 µg subcutaneously (SC) to elicit a measurable GH pulse; some protocols span 100–500 µg depending on body mass and study design.
- Repeated-dosing research regimens typically use 200 µg SC two to three times daily (e.g., morning and pre-sleep) to sustain elevated GH/IGF-1 over days to weeks.
- Subcutaneous injection is the standard route; intravenous administration produces faster peak levels but is rarely used outside controlled research. No established therapeutic dose exists — published regimens vary, and medical supervision is required.
Best practices
- Administer subcutaneously into abdominal or thigh tissue; rotate injection sites to minimize local irritation.
- Timing strategies used in research: before sleep or in a fasted state in the morning, to align with endogenous GH secretory patterns. Exercise proximity may enhance GH responsiveness, though this is not well characterized for ipamorelin specifically.
- Use only pharmaceutical-grade preparations under medical supervision. Baseline and periodic monitoring of IGF-1, fasting glucose, and insulin are appropriate with repeated use.
Literature and references
Ghrelin is a growth-hormone-releasing acylated peptide from stomach
Nature • 1999
Discovery of ghrelin as the endogenous GHS-R1a ligand, establishing the physiological receptor pathway that synthetic secretagogues such as ipamorelin target.
Ipamorelin, the first selective growth hormone secretagogue
European Journal of Endocrinology • 1998
Characterization of ipamorelin's selectivity for GH release relative to cortisol and prolactin compared with earlier GHRPs in animal and early human data.
Common questions
Is ipamorelin approved for medical use?
No. Ipamorelin is an investigational compound not approved by major regulatory agencies for anti-aging, performance enhancement, or standard clinical use. It may be used under approved research protocols or with specialist medical oversight, but widespread off-label use involves unregulated products with uncertain purity and dosing.
How quickly does ipamorelin raise growth hormone?
After subcutaneous injection, GH levels typically rise within minutes and peak around 30–60 minutes post-dose. The peptide is short-lived, but repeated dosing can sustain elevated IGF-1 over time.
Can ipamorelin increase appetite?
Ipamorelin acts via the ghrelin receptor, which plays a role in appetite regulation. Increased appetite is a plausible effect, reported in some studies and by users, though responses are variable and may be transient.
Is long-term ipamorelin use safe?
Long-term safety has not been established. Chronic GH/IGF-1 elevation carries risks including impaired glucose metabolism and theoretical concern for neoplasm promotion in susceptible individuals. Long-term use should involve clinical monitoring and informed discussion of these uncertainties.
Can ipamorelin improve exercise recovery?
Some research protocols time dosing around sleep or exercise to align with natural GH pulses. Short-term studies suggest potential effects on recovery markers, but robust clinical evidence that ipamorelin meaningfully improves training outcomes in healthy individuals is lacking.